UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months
July 20, 2016 9:48 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results. The analyst continues to expected FDA approval in the next few months.
Gilson commented, "Sarepta on July 19 reported 2Q16 financial results, ending the... More
Stocks with Implied Volatility Movement
July 18, 2016 5:11 AM EDTSarepta Therapeutics (SRPT), Rite Aid (RAD) implied volatility is above its IV index mean
... MoreSanthera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - Oppenheimer
July 15, 2016 10:58 AM EDTOppenheimer analyst, Michele Gilson reiterated her Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) after Santhera announced today that the FDA did not support its plans to file an NDA for Raxone (idebenone) for the treatment of DMD. We do not view this as a... More
